Antibody research company Kymab implements ConturELN
The Cambridge-based biopharmaceutical company Kymab has implemented the Electronic Laboratory Notebook system ConturELN. The system will be used for research documentation and knowledge sharing, and to allow the rapid assessment of progress in order to streamline the company’s R&D process.
Founded in 2009, Kymab is a biopharmaceutical company engaged in the discovery and development of human monoclonal antibody therapeutics. By using its proprietary KymouseTM platform, research is expected to lead to the discovery of highly potent therapeutic antibodies with excellent affinities and neutralizing capability, previously only possible through in vitro and in vivo technologies in the industry.
As a new, dynamic and fast moving company Kymab needed to adopt the most efficient methods of recording their experimental work in order to allow the rapid assessment of progress, to identify road-blocks and capitalize on the talented scientists that are part of their team.
Several Electronic Laboratory Notebook solutions were thoroughly evaluated before ConturELN was chosen, as providing the right balance between functionality with an easy learning curve and enterprise features such as IP witnessing and Oracle support etc.
"We have focused at an early stage on the ability to access and perpetuate valuable research material in an electronic format. This will allow us to leverage our data to the best possible extent across a variety of research and development projects. Our scientists are enthusiastic about using an electronic laboratory notebook solution. Contur ELN provides an excellent balance between rich-content and usability", says Mark Strivens, Vice President, Bioinformatics at Kymab.
"We are pleased to welcome Kymab on board as customers. This further confirms that ConturELN is an optimal solution for biopharma companies looking for a robust and secure yet user friendly and cost effective ELN solution", says Thomas Rozlucki, CEO at Contur Software.
About Kymab Limited
Kymab is a biopharmaceutical company engaged in the discovery and development of human monoclonal antibody therapeutics. Despite the prevalence and importance of the monoclonal antibody class of drugs, the industry has been relying on in vitro and in vivo technologies to generate antibodies that are not optimal and do not adequately replicate the full potential of the human immune system. Kymab is creating a mouse-based antibody discovery technology, the KymouseTM, with a superior repertoire of B-cell mediated immune response that is expected to lead to the discovery of highly potent therapeutic antibodies with excellent affinities and neutralizing capability.